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Background: Despite the strong preclinical rationale, there are only very few data considering 
the utility of metformin as a potential pain therapeutic in humans. The aim of this study was 
to determine the association between metformin therapy and pressure pain threshold (PPT) in 
lean women with polycystic ovary syndrome (PCOS). We hypothesized that metformin therapy 
in lean PCOS women increases PPT.
Materials and methods: Twenty-seven lean PCOS women with free androgen index 
phenotype .5 and 18 lean healthy controls were enrolled in the study. Fifteen of the PCOS 
women were randomly assigned to be treated with metformin 1,500 mg daily for 6 months. 
PPT and plasma β-endorphin levels were measured in all women at the beginning of the study 
and after 6 months of observation.
Results: We observed an increase in PPT values measured on deltoid and trapezius muscle in 
the PCOS with metformin group after 6 months of metformin administration (4.81±0.88 kg/cm², 
P,0.001 on deltoid muscle, and 5.71±1.16 kg/cm² on trapezius muscle). We did not observe 
any significant changes in PPT values in the PCOS without treatment group and in controls. 
We did not observe any significant changes in serum β-endorphin levels in any studied groups 
during the 6-month observation.
Conclusion: We conclude that metformin therapy increases PPT in lean PCOS women, with-
out affecting plasma β-endorphin concentration. Our results may suggest the potential role of 
metformin in pain therapy. We propose that larger, randomized studies on metformin impact 
on pain perception should be performed.
Keywords: metformin, pressure pain threshold, pressure algometry, polycystic ovary syndrome, 
pain therapy
Introduction
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders 
in women. Not only does it impact the fertility of the patients, but it also increases 
the risk of metabolic disorders. Some evidence indicates that the evolution of 
PCOS is related to the activity of the endogenous opioid system, in which the main 
molecule β-endorphin is produced by the pituitary gland and may contribute to PCOS 
pathogenesis through central effects on gonadotropin secretion and peripheral effects 
on glucose metabolism.1–4 In our earlier study, we found higher plasma β-endorphin 
level in lean PCOS women compared to the healthy controls.4 Some data have reported 
that plasma opioid levels correlate with pain perception and pain threshold.5–7
Metformin, an antidiabetic drug of the biguanide class, is now one of the most 
widely used drugs in the treatment of PCOS.8–11 Metformin activates adenosine 
monophosphate-activated protein kinase (AMPK) and, through AMPK activation, 
inhibits the mammalian target of rapamycin (mTOR) pathway.12–15 AMPK may 
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play a role in the pain mechanism pathway. Preclinical 
neuropathic and postsurgical pain studies implicate the 
AMPK as a potential pharmacological target for the treatment 
of chronic pain conditions. By inhibiting mTOR signaling in 
nociceptors, metformin has been shown to reduce mechanical 
allodynia and nociceptor excitability.12–15 Despite the strong 
preclinical rationale, there are only very few data, some of 
them case reports, considering the utility of metformin as 
a potential pain threshold modifier in humans.14,16,17
Given the effect of metformin therapy on pain perception, 
the objective of our study was to determine the association 
between metformin therapy and pressure pain threshold 
(PPT) in lean PCOS women. Earlier studies have demon-
strated the role of β-endorphins and testosterone in this 
process. We hypothesized that metformin therapy in lean 
PCOS women would increase PPT.
Materials and methods
Forty-five lean women with body mass index (BMI) within 
the normal range (18.5–24.9 kg/m²) – 27 with PCOS and 18 
without this disorder – were enrolled in the study and divided 
into three groups.
PCOS patients were divided into two groups. The first 
group consisted of 15 PCOS women who were treated with 
1,500 mg metformin per day for 6 months. The second group 
consisted of twelve PCOS women who did not receive any 
medical therapy. Patients were assigned to groups randomly. 
The diagnosis of PCOS among all examined patients was 
based on the Androgen Excess Society criteria.1 We included 
patients with free androgen index (FAI) phenotype $5. 
Hyperprolactinemia, androgen-secreting tumors, Cushing’s 
disease, and congenital adrenal hyperplasia were excluded 
based on clinical and laboratory data.
The control group consisted of 18 healthy lean volun-
teers, who had regular menstrual cycles, without laboratory 
and clinical signs of hyperandrogenism. All patients had an 
FAI of ,5 and did not receive any medical therapy over the 
entire period of the study.
All 45 subjects had normal renal and hepatic function 
and had not received any medication for at least 6 months 
before the study. Patients who showed evidence of thyroid 
dysfunction, diabetes, musculoskeletal disorders, or other 
internal pathologies were excluded from the study. Patients 
were also excluded if they exhibited any of following: symp-
toms in the neck, head, or upper extremities, previous history 
of motor organs injury, receiving any soft tissue therapy 
within the past 12 months, and regular use of analgesic or 
anti-inflammatory drugs.
There were no significant differences in BMI, age, 
prolactin, cortisol, estradiol, glucose in oral glucose tolerance 
test (OGTT), and thyroid hormones levels between the three 
studied groups at the beginning of the study. The clinical 
characteristics of all groups are listed in Table 1.
Each patient underwent a full clinical evaluation. Fasting 
blood samples were collected at 0800 hours from a forearm 
vein between days 1 and 5 of the menstrual cycle. The follow-
ing were the parameters measured: luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), estradiol, testosterone, 
triiodothyronine (FT3), thyroid-stimulating hormone 
(TSH), thyroxin (FT4), sex hormone-binding globulin 
(SHBG), cortisol at 0800 hours and 1700 hours, prolactin, 
insulin, and glucose by OGTT, all according to the routine 
methods. Free testosterone was calculated by using the FAI 
ratio – the total testosterone level (nmol/L) was divided by 
the SHBG level (nmol/L) and then multiplied by 100. All 
parameters were measured two times – at the beginning of 
the study and after 6 months observation.
β-Endorphin measurement
Levels of endorphins were measured using the Endorphin 
beta (human) RIA Kit RK-022-14 (Phoenix Pharmaceuticals, 
Inc., Burlingame, CA, USA) and calculated according to the 
Assay Protocol.4,18 In all patients, the β-endorphins concen-
trations were measured two times – at the beginning of the 
study and after 6 months observation.
PPT assessment
The PPT, defined as the pressure at which the sensation 
changed from pressure to pain, has been recognized as an 
effective and reliable way to quantify pain measures.19–22 
In our study, PPT was measured using an electronic, wireless 
algometer (Commander Echo® Algometer, JTECH Medical, 
Midvale, UT, USA). The reliability of pressure algometry has 
been found to be high.23 The Algometer has a circular 1-cm² 
tip applying a rate of pressure of 1 kg/s as standard. PPTs 
were measured in the midpoint of the anterior fibers of the 
deltoid muscle and on the upper fibers of the trapezius muscle 
(medial to the superior angle of the scapula), both in the 
nondominant side.24,25 Pressure was applied at a straight angle 
to the defined surface of the specified point. The examiner 
increased the pressure at the rate of 1 kg/s until the subject 
experienced pain. The participants were instructed to verbally 
express their first perception of pain. Three PPTs were mea-
sured at each designated point, so an average PPT at each 
point could be ascertained. Testing points were marked with a 
water-soluble pen to ensure reliable and rapid location during 
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the experimental procedure. All patients were investigated by 
the same doctor, who underwent professional training accord-
ing to JTECH Medical guidelines and completed 30 hours 
of practice before data collection. The investigator was not 
directly connected with the study to ensure objective results, 
and did not know to which study group the patient belonged. 
The study patients tested never viewed the recorded values. 
In all patients, the PPT values were measured two times – at 
the beginning of the study and after 6 months observation.
The study was performed in the Department of 
Gynecological Endocrinology, Jagiellonian University 
Hospital, Cracow, Poland. The study was approved by the 
Bioethics Committee at the Collegium Medicum, Jagiellonian 
University in Cracow, Poland (Resolution No KBET/249/
B/2014), and informed consent was signed by each woman.
statistical analysis
Clinical and laboratory parameters, expressed on a continu-
ous scale, were presented as means with standard deviations. 
Data did not present any significant outliers. Kolmogorov–
Smirnov test revealed a normal distribution of data. Compari-
sons in baseline parameters between groups were performed 
using analysis of variance (ANOVA). Changes in time after 
adjustment to the study groups were verified using ANOVA 
with repeated measures. In case of significant interaction 
between time and study group, paired t-test was also 
performed in each group. Finally, because of the simplicity of 
presentation, changes in all studied parameters in time were 
described in the metformin-treated PCOS group.
The mean of three PPT measurements executed at 
each designated point was applied in all calculations, their 
degree of consensus in terms of absolute agreement were 
verified using intraclass correlation coefficient (ICC), which 
is recommended to assess the degree of reproducibility 
of measurements. The 95% confidence interval (CI) and 
standard error of measurement (SEM) were also calculated to 
give an indication of the magnitude of disagreement between 
the PPT measurements.
Table 1 clinical characteristics of lean women with polycystic ovary syndrome and controls at the beginning of the study
Parameter Total
n=45
mean ± SD
PCOS with 
metformin group (1)
n=15
mean ± SD
PCOS without 
treatment group (2)
n=12
mean ± SD
Control group (3)
n=18
mean ± SD
P-value
age (years) 23.3±2.81 23.27±3.24 23.83±2.89 22.89±2.47 P=0.45
Weight (kg) 60±4.5 60.33±3.5 59.83±2.86 60.33±6.08 P=0.38
height (cm) 167.7±3.78 168.8±1.75 168.8±1.75 166±5.25 P=0.39
BMI (kg/m²) 21.44±1.47 21.19±1.27 21.1±1.01 21.87±1.8 P=0.63
FT3 (pmol/L) 4.54±0.49 4.41±0.49 4.52±0.42 4.67±0.62 P=0.32
TSH (IU/mL) 1.8±0.59 1.99±0.62 1.51±0.33 1.83±0.64 P=0.45
FT4 (pmol/L) 13.62±2.09 13.01±2.2 13.61±1.4 14.13±2.32 P=0.29
Prolactin (µIU/mL) 248.4±87.14 243.9±87.18 271.5±81.2 236.7±92.7 P=0.22
Estradiol (pmol/L) 276.2±113.7 270.8±113.7 289.8±96.7 271.6±169.1 P=0.11
LH (mIU/mL) 8.85±3.36 11.46±2.74 10.51±1.98 5.57±1.03 P1,2=0.48, P1,3,0.001, P2,3,0.001
FSH (mIU/mL) 6.16±1.14 6.87±1.08 5.99±0.62 5.69±1.2 P1,2=0.09, P1,3=0.008, P2,3=0.72
Testosteron (nmol/L) 1.96±0.76 2.51±0.34 2.51±0.28 1.14±0.42 P1,2=0.1, P1,3,0.001, P2,3,0.001
SHBG (nmol/L) 41.57±8.07 37.59±6.33 39.78±4.43 46.06±9.23 P1,2=0.72, P1,3=0.006, P2,3=0.07
Fai 5.06±2.32 6.97±1.47 6.32±0.45 2.64±1.23 P1,2=0.33, P1,3,0.001, P2,3,0.001
Cortisol-0800 hours (µm/dL) 20.5±7.63 21.5±6.82 20.5±5.82 19.7±5.82 P=0.25
Cortisol-1700 hours (µm/dL) 10.3±4.78 11.3±4.48 10.2±4.67 9.5±4.33 P=0.19
glucose 0′ (mmol/L) 5.1±0.95 4.8±0.6 5.0±0.86 5.4±1.15 P=0.17
glucose 60′ (mmol/L) 5.7±1.4 5.5±1.44 5.6±1.34 5.8±1.38 P=0.18
glucose 120′ (mmol/L) 5.41±1.14 5.1±0.92 5.2±0.94 5.0±1.34 P=0.38
insulin 0′ (µU/mL) 11.6±5.43 14.4±5.49 14.84±2.45 8.9±3.84 P1,2=0.54, P1,3=0.003, P2,3=0.003
insulin 60′ (µU/mL) 62.5±34.83 83.8±32.26 85.6±20.21 42.6±24.12 P1,2=0.43, P1,3,0.001, P2,3,0.001
insulin 120′ (µU/mL) 55.9±35.5 78.2±35.48 76.34±31.3 35.1±19.62 P1,2=0.32, P1,3,0.001, P2,3,0.001
β-Endorphins (pg/mL) 12.01±4.95 16.22±2.04 14.84±2.45 6.61±1.97 P1,2=0.22, P1,3,0.001, P2,3,0.001
PPT deltoid muscle (kg/cm²) 7.82±2.55 9.56±1 9.91±1.4 4.96±0.55 P1,2=0.63, P1,3,0.001, P2,3,0.001
PPT trapezius muscle (kg/cm²) 6.79±1.89 7.96±0.98 8.4±0.94 4.74±0.6 P1,2=0.38, P1,3,0.001, P2,3,0.001
Notes: Data are presented as mean ± SD. Analysis was carried out using ANOVA test. Significance level ,0.05.
Abbreviations: BMI, body mass index; FT3, triiodothyronine; TSH, thyroid-stimulating hormone; FT4, thyroxin; SHBG, sex hormone-binding globulin; FAI, free androgen 
index; LH, luteinizing hormone; FSH, follicle-stimulating hormone; PPT, pressure pain threshold; PCOS, polycystic ovary syndrome.
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Statistical analysis was made using Statistica 12 (Statsoft, 
Tulsa, OK, USA). Pearson correlations were used to assess 
the relation between pain threshold and β-endorphin levels.
Results
The main clinical characteristics of the study population at 
the beginning of the study are shown in Table 1. The PCOS 
women from both groups and controls were of a similar age 
and had a similar BMI. There were no significant differences 
in prolactin, estradiol, cortisol at 0800 hours and 1700 hours, 
glucose in OGTT, and thyroid hormones levels between 
the three studied groups. There were significant differences 
in LH, FSH, testosterone, SHBG, insulin in OGTT levels, 
and FAI ratios between PCOS women and controls. PCOS 
women have higher plasma β-endorphin levels and PPT 
values measured on deltoid and trapezius muscles than 
healthy controls.
ICC and SEM determined at specific points (Table 2), 
calculated separately for measurements performed at 
the beginning of the study and after 6 months observa-
tion, demonstrated strong reliability at both tested points 
(ICC =0.983–0.999).
We observed significant interactions between time and 
study group in PPT levels (P,0.001). Figure 1 presents 
changes in PPT values measured on deltoid and trapezius 
muscles in all studied groups during the entire period of 
observation. We observed a significant increase in PPT values 
measured on deltoid and trapezius muscles only in the PCOS 
in the metformin group (4.81±0.88 kg/cm² on deltoid muscle 
and 5.71±1.16 kg/cm² on trapezius muscle, P,0.001). There 
were no significant changes in PPT values in time observed 
in the PCOS without treatment group and controls.
We did not observe any significant changes in time in 
serum β-endorphin levels in any studied groups during 
6 months observation (Figure 2).
Significant interactions between time and study group 
were observed also in insulin, testosterone, LH, FAI, and 
SHGB levels. Table 3 presents the comparison of all evaluated 
parameters in women from group 1 at the beginning of the study 
and after 6 months of metformin administration. We observed 
a decrease in testosterone level (-0.71±0.37 nmol/L, 
P,0.001) and an increase in SHBG level (9.13±6.51 nmol/L, 
P,0.001), and as a result, a significant decrease in the FAI 
ratio (-3.06±1.65, P,0.001) after 6 months of metformin 
therapy in lean PCOS women. We also observed a decrease 
in LH level (-5.91±1.95 mIU/mL, P,0.001) and insulin in 
OGTT levels (0′: -4.4±2.12 µU/mL, 60′: -33.6±14.89 µU/mL, 
120′: -34.33±10.3 µU/mL, P,0.001) after 6 months 
metformin administration in group 1.
We did not observe any significant changes in those hor-
monal parameters during the 6 months observation in PCOS 
without treatment group nor in healthy controls.
Discussion
To the best of our knowledge, this study is the first to address 
the question of whether there are changes in PPTs in lean 
women with PCOS after metformin therapy. We also tried to 
determine whether there were any changes in β-endorphins 
and testosterone levels in lean PCOS women after 6 months 
metformin administration.
The use of metformin in PCOS women is associated with 
a more regular menstrual cycle, improved ovulation, and a 
reduction in circulating androgen levels.10,11 In preclinical 
pain models, metformin, as an AMPK activator, has been 
shown to be remarkably effective in reducing mechanical 
allodynia and nociceptor excitability.12,26–29 Moreover, the 
activation of AMPK with metformin has led to decrease 
pain in neuropathic and postsurgical pain models, suggest-
ing that these drugs and this mechanism of action might be 
effective in humans.30 Labuzek et al17 described a successful 
case of pain management using metformin in a patient with 
adiposis dolorosa. Taylor et al16 revealed that metformin use 
is associated with a decrease in pain in patients with lumbar 
radiculopathy. They proposed that metformin might have 
clinical utility for chronic pain conditions involving injury 
to the peripheral nervous system. On the other hand, Smith 
et al14 in their study concluded that the use of metformin was 
not associated with lower pain scores in diabetes patients. It is 
unclear what the dose and duration of metformin therapy is 
necessary to activate the AMPK pathway in humans to result 
in clinically significant pain reduction.
Because metformin is commonly prescribed for PCOS 
women, we could have tested the hypothesis that metformin 
Table 2 ICC, 95% CI, and SEM of PPT values at each measure-
ment point at the beginning of the study and after 6 months 
observation
Parameter ICC 95% CI SEM (kg/cm²)
PPT-deltoid muscle  
(beginning of the study)
0.990 0.983–0.994 0.254
PPT-trapezius muscle  
(beginning of the study)
0.998 0.997–0.999 0.186
PPT-deltoid muscle  
(after 6 months)
0.990 0.983–0.994 0.188
PPT-trapezius muscle  
(after 6 months)
0.997 0.999–0.998 0.213
Abbreviations: ICC, intraclass correlation coefficient; CI, confidence interval; 
seM, standard error of measurement; PPT, pressure pain threshold.
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would have an impact on pain perception in this group of 
patients. Because of studies that showed that β-endorphin 
levels are directly correlated to patients’ body weight, we 
first performed our study on lean patients only to elimi-
nate the possible influence of overweight and obesity for 
β-endorphins and other hormonal parameters.1,4 Second, 
we decided to limit our group of PCOS patients only to the 
lean ones to avoid the effect of fat tissue on plasma insulin 
and testosterone levels during metformin treatment. As the 
lean PCOS patients also benefit from metformin treatment 
in regard to reduction of androgenicity, we decided to carry 
out the study on lean ones. The other reason we decided to 
choose lean patients was that the subcutaneous fat layer of 
overweight and obese PCOS subjects may interfere with 
the readings of the Algometer.
We tested this hypothesis through PPT measurements. 
PPT has been recognized as an effective and reliable way 
to quantify pain measures.19–22 In the beginning of the 
study, PPT values were higher in both PCOS groups than in 
healthy controls, which could be the cause for higher plasma 
β-endorphin levels in PCOS patients. Some studies, as well 
as our earlier findings showed a connection between the 
high level of endorphins and the pathogenesis of PCOS.3,4,31 
Several studies have reported that plasma opioid peptide 
levels correlate with pain perception index measured from 
cutaneous tissues.5–7 It was found that a higher concentration 
of endorphins was associated with an increased peripheral 
PPT.6 Sheps et al7 showed an association between increased 
plasma β-endorphin levels and peripheral PPT. Moreover, 
some studies have shown that testosterone has an antian-
algesic effect.32 Studies in humans have indicated that tes-
tosterone levels are positively correlated with activation in 
the middle frontal cortex during electrical and thermal pain 
stimulation, leading to a decrease in pain perception.33,34 Choi 
et al34 revealed that a decrease in the level of testosterone is 
a possible factor contributing to the increase in pain sensa-
tion during the stressful condition. Although studies were 
performed on males only, it could indicate the impact of 
testosterone on pain perception. In our opinion, it could be 
interesting in the light of latest reports that revealed a higher 
prevalence of self-harm in PCOS women than in healthy 
controls.35 To the best of our knowledge, there are no studies 
that evaluated the connection between testosterone levels 
and pain perception in lean PCOS women. All mentioned 
findings could explain differences that we observed between 
PCOS women and healthy controls in the beginning of the 
study. However, in our study, there were no differences 
in FAI ratios, plasma β-endorphin levels, and PPT values 
Figure 1 estimated marginal means of PPT values measured on deltoid and trapezius muscle at the beginning of the study and after 6 months of observation in all 
studied groups. Analysis was carried out using ANOVA test with repeated measures. Significance level ,0.05.
Abbreviations: PPT, pressure pain threshold; PcOs, polycystic ovary syndrome.
Figure 2 estimated marginal means of plasma β-endorphins levels at the beginning 
of the study and after 6 months of observation in all studied groups.
Note: analysis was carried out using anOVa test with repeated measures. 
Significance level ,0.05.
Abbreviation: PcOs, polycystic ovary syndrome.
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between the two PCOS groups, so data from the beginning 
of the study can be compared. In the PCOS with metformin 
group, after 6 months therapy, we observed a significant 
increase in PPTs in both measurement points (Figure 1). 
There were no differences in PPT values in the PCOS without 
treatment group and healthy controls. An increase in PPTs 
values was followed by a decrease in testosterone levels. 
Moreover, there were no differences in plasma β-endorphin 
levels after 6 months of metformin administration (Figure 2), 
so the increase in PPTs values could not be caused by 
an increase in testosterone levels or changes in plasma 
β-endorphin concentration, which can be explained by earlier 
findings.3–7,32–34 It may indicate the role of AMPK activation 
and concomitant decreases in mTOR activity by metformin 
in its effect on increased pain perception in PCOS women. 
Our findings are in agreement with studies that suggested 
metformin could be considered a potential pain therapeutic 
in humans.16,17 It has been argued whether metformin acts as 
an analgesic or only as an antihyperalgesic agent in chronic 
pain conditions. Some studies suggest that this drug has only 
antihyperalgesic effect,16,17 but our findings may give new 
insight into the problem.
Insulin resistance and hyperinsulinemia affect 65%–70% 
of women with PCOS.36 The benefits of metformin on 
insulin sensitivity have been demonstrated in nondiabetic 
women with PCOS.8–11 In our study, we observed a decrease 
in insulin levels in OGTT after 6 months of metformin 
administration, which is consistent with the results of 
earlier studies.8–11
It has been suggested that metformin reduces hyperan-
drogenism through its effect on both the ovary and adrenal 
gland, suppressing their androgen production, reducing 
pituitary LH, and increasing the production of SHBG by the 
liver.37 Our results are consistent with earlier findings.8,9,37 
We observed a decrease in testosterone and an increase in 
SHBG levels as well as a decrease in LH levels. The changes 
in testosterone and SHBG levels resulted in a decrease in 
the FAI ratio in lean PCOS women after 6 months of met-
formin administration. In the same 6 months, we observed an 
increase in PPTs values, which may suggest the possible link 
Table 3 clinical characteristics of lean women from the PcOs with metformin group (1) at the beginning of the study and after 6 
months metformin therapy
Parameter PCOS with 
metformin group
n=15 (beginning 
of the study)
PCOS with 
metformin group
n=15 (after 6 months 
metformin therapy)
Mean difference in parameters 
between 6 months and baseline 
in PCOS with metformin
group 
P-value
Weight (kg) 60.33±3.5 59.67±3.46 -0.67±1.54 0.12
BMI (kg/m²) 21.19±1.27 20.95±1.23 -0.24±0.54 0.11
FT3 (pmol/L) 4.41±0.49 4.51±0.76 0.1±0.52 0.46
TSH (IU/mL) 1.99±0.62 1.98±0.57 -0.01±0.03 0.12
FT4 (pmol/L) 13.01±2.2 13.2±1.7 0.09±0.67 0.63
Prolactin (µIU/mL) 243.9±87.18 239.67±85.17 -4.27±23.62 0.49
Cortisol-0800 hours (µm/dL) 21.5±6.82 19.8±5.08 -1.7±2.65 0.45
Cortisol-1700 hours (µm/dL) 11.3±4.48 10.9±4.34 -0.4±2.12 0.33
Estradiol (pmol/L) 270.8±113.7 270.33±98.42 -0.47±31.3 0.96
LH (mIU/mL) 11.46±2.74 5.55±1.51 -5.91±1.95 ,0.001
FSH (mIU/mL) 6.87±1.08 6.79±1.04 -0.08±0.96 0.39
Testosterone (nmol/L) 2.51±0.34 1.8±0.29 -0.71±0.37 ,0.001
SHBG (nmol/L) 37.59±6.33 46.7±4.75 9.13±6.51 ,0.001
Fai 6.97±1.47 3.91±0.73 -3.06±1.65 ,0.001
glucose 0′ (mmol/L) 4.8±0.6 4.67±0.34 -0.13±0.28 0.47
glucose 60′ (mmol/L) 5.5±1.44 5.2±0.1.23 -0.3±0.63 0.54
glucose 120′ (mmol/L) 5.1±0.92 5.0±0.87 -0.1±0.43 0.67
insulin 0′ (µU/mL) 14.4±5.49 10.2±3.45 -4.4±2.12 ,0.001
insulin 60′ (µU/mL) 83.8±32.26 50.2±28.97 -33.6±14.89 ,0.001
insulin 120′ (µU/mL) 78.2±35.48 43.87±21.23 -34.33±10.3 ,0.001
β-Endorphins (pg/mL) 16.22±2.04 15.46±1.82 -0.76±1.93 0.15
PPT deltoid muscle (kg/cm²) 9.56±1 14.37±0.94 4.81±0.88 ,0.001
PPT trapezius muscle (kg/cm²) 7.96±0.98 13.67±0.76 5.71±1.16 ,0.001
Notes: Data are presented as mean ± sD. analysis was carried out using t-test for dependent samples. Significance level ,0.05.
Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index; FT3, triiodothyronine; TSH, thyroid-stimulating hormone; FT4, thyroxin; SHBG, sex hormone-
binding globulin; FAI, free androgen index; LH, luteinizing hormone; FSH, follicle-stimulating hormone; PPT, pressure pain threshold.
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between these two phenomena. This link may require further 
study evaluating the effect of other testosterone-reducing 
medications on PPT values.
Limitations
The main limitation of the present study is the small number 
of patients investigated. In our opinion, larger prospective 
trials are needed to test the hypothesis that metformin might 
impact on pain perception. The other possible limitation is 
collecting only single plasma samples to assess β-endorphin 
levels. We took samples on the same days of menstrual 
cycles, and PPT measurement and blood collection were 
performed at the same time. Another limitation could be 
only single-day PPT measurement and the length of the 
study. However, some studies showed no differences in PPT 
values over consecutive days of testing.38 Determinations of 
pain threshold are, by their nature, subjective and affected by 
habituation. It could be interesting to continue the study to 
12 or 18 months so as to evaluate the influence of the long-
term effect of metformin on PPT.
Conclusion
We conclude that metformin therapy increased PPT in lean 
PCOS women, without affecting plasma β-endorphin con-
centration. In addition, we found a decrease in testosterone, 
LH, and insulin and an increase in SHBG levels in the lean 
PCOS patients after 6 months metformin administration. 
Our results may suggest the potential role of metformin in 
pain therapy in humans and confirm the beneficial effect on 
hormonal parameters in PCOS women.
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